Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025
Kelsey M. Sumner, Emma K. Noble, Lauren B. Grant, Jessica R. Meeker, Vel Murugan, Lora Nordstrom, Stacey L. House, Rachel M. Presti, Emmanuel B. Walter, Olivia L. Williams, Elie A. Saade, David H. Canaday · 2026
Read Comparative immunogenicity and relative vaccine efficacy of recombinant and cell culture-based influenza vaccines: Results from a randomized trial of adults in the United States, 2024-2025 by Kelsey M. Sumner, Emma K. Noble, Lauren B. Grant, Jessica R. Meeker, Vel Murugan, Lora Nordstrom, Stacey L. House, Rachel M. Presti, Emmanuel B. Walter, Olivia L. Williams, Elie A. Saade, David H. Canaday (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13648820.txt.
Description
Kelsey M. Sumner and colleagues ran a trial of two flu shots that skip egg growth, for the 2024-2025 US season. One shot is built from pure virus protein made in cells. The other grows the virus in cell culture. Past proof on which shields best was thin.
The trial gave 591 adults, aged 18 to 64, one shot or the other by chance. Teams then watched for flu-like illness for six months and tested the sick. Flu A struck about 2 in 100 of the protein shot group and about 6 in 100 of the cell shot group. Blood tests in a subset showed stronger blocks on the virus coat for the protein shot. The authors say it shielded better that season.
Catalog record
| CREATOR | Kelsey M. Sumner, Emma K. Noble, Lauren B. Grant, Jessica R. Meeker, Vel Murugan, Lora Nordstrom, Stacey L. House, Rachel M. Presti, Emmanuel B. Walter, Olivia L. Williams, Elie A. Saade, David H. Canaday |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| LICENSE | https://creativecommons.org/publicdomain/zero/1.0 |
| RIGHTS | CC0 |
| SOURCE | Europe PMC |